FACTORS ASSOCIATED WITH THE USE OF IMMUNE CHECKPOINT INHIBITORS IN OLDER ADULTS WITH METASTATIC NON-SMALL CELL LUNG CANCER AND PRE-EXISTING AUTOIMMUNE DISEASE: A SEER-MEDICARE STUDY

被引:0
|
作者
Gohil, S. [1 ]
Chen, H. [2 ]
Lewis, W. E. [3 ]
Trivedi, M. [2 ]
Aparasu, R. R. [2 ]
Johnson, M. L. [2 ]
机构
[1] Univ Houston, Coll Pharm, Durham, NC USA
[2] Univ Houston, Coll Pharm, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
关键词
D O I
暂无
中图分类号
F [经济];
学科分类号
02 ;
摘要
HSD75
引用
收藏
页码:S234 / S234
页数:1
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    BULLETIN DU CANCER, 2016, 103 : S138 - S143
  • [22] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [23] Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease
    Goutam, S.
    Raghavan, A.
    Meyers, D. E.
    Dawe, D.
    Oneil, L.
    Graham, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S870 - S870
  • [24] Proton Pump Inhibitors' Impact on the Effectiveness of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer
    Edwards, A. L.
    Walker, D.
    Dumais, K.
    Powery, H.
    Linares, J.
    Raez, L. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S634 - S635
  • [25] ECONOMIC BURDEN ASSOCIATED WITH IMMUNERELATED ADVERSE EVENTS INDUCED BY IMMUNE CHECKPOINT INHIBITORS AMONG OLDER ADULTS WITH NON-SMALL CELL LUNG CANCER
    Rong, Y.
    Ramachandran, S.
    Bhattacharya, K.
    Yang, Y.
    Chang, Y.
    Earl, S.
    Bentley, J.
    VALUE IN HEALTH, 2023, 26 (06) : S66 - S66
  • [26] Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer
    Shannon, Vickie R.
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (04) : 326 - 340
  • [27] Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer
    Cunha, R.
    Fernandes, M.
    Abreu, S.
    Oliveira, C.
    Dias, J.
    Alves, S.
    Rodrigues, A.
    Oliveira, J.
    Pousa, M. I.
    Soares, M.
    Azevedo, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S1432 - S1432
  • [28] Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer
    Kuo, Chih-Hsi Scott
    Wang, Chin-Chou
    Huang, Yu-Chen
    Pavlidis, Stelios
    Liu, Chien-Ying
    Ko, How-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Wang, Chih-Liang
    Guo, Yi-Ke
    Yang, Cheng-Ta
    THORACIC CANCER, 2019, 10 (05) : 1158 - 1166
  • [29] Safety of Palliative Radiotherapy and Immune Checkpoint Inhibitors in Patients with Metastatic Non-Small Cell Lung Cancer
    Tjong, M.
    Ragulojan, M.
    Poon, I.
    Cheng, S.
    Doherty, M.
    Ung, Y.
    Cheung, P.
    Cheema, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S667 - S668
  • [30] The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
    Nicos, Marcin
    Krawczyk, Pawel
    Crosetto, Nicola
    Milanowski, Janusz
    FRONTIERS IN ONCOLOGY, 2020, 10